Table 3.

Current clinical trials using NK cell based immune therapy in cutaneous melanoma.

Clinical Trials.Gov ID	Study Drug(s)	Mechanism of Study Agent Utilizing NK Cell Anti-Tumor Effect
NCT03841110 Phase I Advanced malignancy (Including melanoma)	FT500 Pembrolizumab Atezolizumab Nivolumab IL-2	FT500 is an allogeneic, off the shelf, NK cell product derived from induced pluripotent stem cell (FT500 administered either as monotherapy, in combination with check point inhibitor, or in combination with check-point inhibitor and IL-2). Study drugs include fludarabine and cyclophosphamide as lympho-conditioning agents
NCT04592653 Phase II Advanced malignancy, including cutaneous melanoma	ALKS 4230 Pembrolizumab	ALKS 4230 is an engineered fusion protein comprised of modified IL-2 designed to selectively expand anti-tumor T cells and NK cells while avoiding activation of immunosuppressive cells [181].
NCT04477876 Cutaneous melanoma	Anti-CD160-TM agonist antibody	Transmembrane isoform of CD160 (CD160-TM) is expressed on activated NK cells. Binding of agonist antibody to CD160-TM can promote NK cell dependent anti-tumor effect [182]
NCT03420963 Phase I Advanced malignancy, including cutaneous melanoma	Ex-vivo expanded allogeneic NK cells	Cord Blood-derived Expanded Allogeneic NK cells are cord-blood derived, expanded ex-vivo and administered to patients after pre-treatment with etoposide and cyclophosphamide